Sp961
MOVING PAST RECRUITMENT TO RETENTION
Date
May 8, 2023
Explore related products in the following collection:
Society: DDW
All symposia are 90-minute sessions, led by two moderators, with a varying number of invited talks. The session may include Q&A which can be included within each speaker’s total presentation time (2-3 minutes at the end) or as a separate block within the session. The session may also include a panel discussion with noted and/or additional speakers. Science type and topic will vary by the session sponsor.
All symposia are 90-minute sessions, led by two moderators, with a varying number of invited talks. The session may include Q&A which can be included within each speaker’s total presentation time (2-3 minutes at the end) or as a separate block within the session. The session may also include a panel discussion with noted and/or additional speakers. Science type and topic will vary by the session sponsor.
Presenter
Tracks
Related Products
IMMUNE EDITING IN THE INVASIVE MARGIN AND NODE DEPOSITS OF COLORECTAL CANCER SELECTS FOR CELLULAR NEIGHBOURHOODS ENRICHED IN PDL1+ CANCER CELLS
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
IL-17 SUPPRESSES PATHOGENESIS AND STEM CELL ACTIVATION WITHIN THE CONTEXT OF CHRONIC <i>HELICOBACTER PYLORI</i> INFECTION
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
GLIAL CONNEXIN-43 HEMICHANNELS ARE CRITICAL DETERMINANTS OF GUT INFLAMMATION IN MOUSE POSTOPERATIVE ILEUS AND REACTIVE HUMAN ENTERIC GLIA
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
SINGLE-CELL INTESTINAL CHANGES IN PEDIATRIC CROHN'S DISEASE BEFORE AND AFTER ANTI-TNF BLOCKADE.
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
